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Estimated DALYs related to pCHIK-CIR incidence by country in Latin America, 2014
Country Casesa pCHIK-CIRb DALYs DALYs per
100 000
Low Upper Low Upper Low Upper
Dominican
Republic
537 712 242 401 269 555 94 885 105 515 911.04 1013.10
El Salvador 135 383 61 031 67 867 23 890 26 566 376.78 418.99
Puerto Rico 28 619 12 901 14 347 5050 5616 148.23 164.83
Colombia 83 832 37 791 42 025 14 793 16 450 30.61 34.04
Guatemala 22 057 9943 11 057 3892 4328 25.16 27.98
Venezuela 37 015 16 686 18 556 6532 7263 21.48 23.89
Nicaragua 3556 1603 1783 627 698 10.32 11.48
Honduras 4086 1842 2048 721 802 8.90 9.90
Costa Rica 238 107 119 42 47 0.86 0.96
Brazil 3050 1375 1529 538 598 0.27 0.30
Panama 54 24 27 10 11 0.25 0.28
Cuba 40 18 20 7 8 0.04 0.05
Mexico 168 76 84 30 33 0.02 0.03
Paraguay 8 4 4 1 2 0.02 0.02
Chile 19 9 10 3 4 0.02 0.02
Ecuador 10 5 5 2 2 0.01 0.01
Argentina 28 13 14 5 5 0.01 0.01
Bolivia 4 2 2 1 1 0.01 0.01
Peru 11 5 6 2 2 0.01 0.01
Uruguay 0 0 0 0 0 0.00 0.00
Total
region
855 890 385 835 429 058 151 031 167 950 25.45 28.31
DALYs, disability-adjusted life-years; CHIK, chikungunya virus disease; pCHIK-CIR,
post-CHIK chronic inﬂammatory rheumatism.
a Suspected, conﬁrmed, and imported.
b Based on previous estimates.3Burden of chikungunya in Latin American
countries: estimates of disability-adjusted
life-years (DALY) lost in the 2014 epidemic
The burden of chikungunya virus disease (CHIK) in Latin
America is an emerging concern, as virus spread is out of control
and recent studies have reported that the disability-adjusted life-
years (DALYs) lost in some parts of the region could be higher than
those during the 2006 epidemics in India.1,2 Recent estimates
indicate that between 385 835 and 429 058 patients in Latin
America will develop post-CHIK chronic inﬂammatory rheuma-
tism (pCHIK-CIR).3 However, the real disease burden and economic
impact remain unknown and there are no current estimates of the
expected disease burden in the region.
In this study, DALYs for pCHIK-CIR in Latin America were
estimated by country, using the method of Murray.4 As no
disability weight is available for pCHIK-CIR, the disability weight
reported for rheumatoid arthritis (RA) (0.233) was used.2,5,6
Expected incident cases progressing to pCHIK-CIR and its duration
were assumed on the basis of those reported previously.3
According to the estimates generated (Table 1), the expected
burden of pCHIK-CIR in many countries is higher than that
reported in the 2006 epidemics in India (25 888 DALYs).2,5,6 In
Latin America the lower limit burden is estimated at 151 031
DALYs during 2014. However, this does not include the acute phase
DALYs lost and thus the burden could be even higher.
The high burden in the Dominican Republic and El Salvador is of
concern, given the socio-economic situation in those countries.
However, the fact that a country such as Venezuela is among those
with the highest burdens is also a worry, since its health system
has shown a decreasing capability for vector-borne disease control
that could lead to an increasing pCHIK-CIR burden.7,8 Furthermore,
the long-running underinvestment in health care that began in
Venezuela in 1998 has persisted until today, such that spraying
campaigns, the distribution of insecticide-treated nets, health
education, and even disease surveillance are no longer working
properly.9 Although other countries in Latin America show lower
DALYs, vector expansion in the context of climate change should
raise attention and lead to the establishment of prevention and
control measures.10,11
Estimates for the dengue burden in the region have indicated
that 69 000 DALYs were lost in 2004. This is two times lower than
the estimate for pCHIK-CIR, suggesting that CHIK could become the
new most important arbovirosis in Latin America in terms of
chronic disability.12 Current arbovirus infections caused by
chikungunya virus, but also by dengue and other emerging
viruses, such as Zika and Mayaro, that have rheumatic manifesta-
tions and share overlapping symptoms, require integrated vector
control, including signiﬁcant community participation and inte-
grated arboviral disease control programs in the endemic countries
of the region.http://dx.doi.org/10.1016/j.ijid.2015.07.015
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).Despite the limitations of this report, to the best of our
knowledge it provides the ﬁrst estimates of DALYs for Latin
America. Previous estimates of the proportion of patients who will
develop pCHIK-CIR are based on data from outside the region,3
hence follow-up of Latin American patients is required in order to
improve the accuracy of pCHIK-CIR estimates. Another limitation
is that the disability weight for RA was used, a disease with an
insidious chronic outcome. Thus, detailed studies estimating the
speciﬁc disability weight for CHIK are urgently needed in the
region.
Finally, there is a need to act in order to achieve CHIK control in
the region. Direct and indirect costs of disease, although unknown,
continue to increase. The effects of pCHIK-CIR epidemics could lead
to fragile health systems being overwhelmed and to an increase in
the burden of other vector-borne diseases. Control strategies must
be approached from a global perspective, since the disease spread
and progression to chronic forms remain out of control.
Fortunately, there is an upcoming dengue vaccine that has
demonstrated an intention-to-treat efﬁcacy of >95% in virologi-
cally conﬁrmed severe dengue in a phase 3 trial that included
20 869 healthy children.13 However, an effective CHIK vaccine is
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